These results suggested that HER2 overexpressed cancer cells may occur in AFP-GC, consisting of heterogeneous subtypes with a better clinical outcome, compared with HER2 non-overexpressed AFP-GC, which consists of homologous cancer cells with aggressive clinical behavior. The gene discussed is AFP; the disease is cancer.